The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...

The biotech—which spun out of BridgeBio Pharma in May 2024—has $100 million to hand, while Helix is bringing $196 million to the table. Combined with $260 million from a planned concurrent ...

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

In addition to approximately $196 million held in Helix Acquisition Corp. II’s trust account (assumed as of the closing and assuming no redemptions by Helix’s public shareholders), the ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public. One year after its initial public offering, Helix Acquisition Corp. II is ...

Right now, some of the world’s top biotech companies are spending millions ... of biology since the discovery of the double helix." ...

While Kirsner points out that a significant portion of investment in AI companies goes to those in the Bay Area, a similar point could be made about investments in Boston-area biotech companies.